Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Operating Income (2019 - 2025)

Goldenwell Biotech's Operating Income history spans 7 years, with the latest figure at -$5885.0 for Q3 2025.

  • For Q3 2025, Operating Income rose 71.93% year-over-year to -$5885.0; the TTM value through Sep 2025 reached $55942.0, up 158.21%, while the annual FY2024 figure was -$27597.0, 11.97% down from the prior year.
  • Operating Income reached -$5885.0 in Q3 2025 per GWLL's latest filing, down from -$3120.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $72165.0 in Q4 2024 to a low of -$920332.0 in Q4 2022.
  • Average Operating Income over 5 years is -$60250.9, with a median of -$20799.0 recorded in 2023.
  • Peak YoY movement for Operating Income: soared 2086.05% in 2021, then tumbled 13946.58% in 2022.
  • A 5-year view of Operating Income shows it stood at -$6552.0 in 2021, then crashed by 13946.58% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then soared by 446.96% to $72165.0 in 2024, then crashed by 108.15% to -$5885.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Operating Income are -$5885.0 (Q3 2025), -$3120.0 (Q2 2025), and -$7218.0 (Q1 2025).